Global Blood Therapeutics Inc: Diferență între versiuni
Global Blood Therapeutics Inc (modificare)
Versiunea de la data 1 octombrie 2024 01:45
, 1 octombrieThe LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Global Blood Therapeutics Inc listata cu simbolul US.GBT ==Descriere companie== Global Blood Therapeutics, Inc.(www.gbt.com) is a biopharmaceutical company that discovers, develops and delivers treatments. The company has introduced Oxbryta (voxelotor) tablets, the Food and Drug Administration (FDA) approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). The...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Global Blood Therapeutics, Inc.(www.gbt.com) is a biopharmaceutical company that discovers, develops and delivers treatments. The company has introduced Oxbryta (voxelotor) tablets, the Food and Drug Administration (FDA) approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). The Company is also focused on its pipeline program in SCD with inclacumab, which is a P-selectin inhibitor in Phase III development to address pain crises associated with the disease. The Company is also in the development of its hemoglobin polymerization inhibitor, GBT601, which is a molecule discovered and designed by scientists at the Company. | Global Blood Therapeutics, Inc.(www.gbt.com) is a biopharmaceutical company that discovers, develops and delivers treatments. The company has introduced Oxbryta (voxelotor) tablets, the Food and Drug Administration (FDA) approved treatment that directly inhibits sickle hemoglobin polymerization, the [[root]] cause of red blood cell sickling in sickle cell disease (SCD). The Company is also focused on its pipeline program in SCD with inclacumab, which is a P-selectin inhibitor in Phase III development to address pain crises associated with the disease. The Company is also in the development of its hemoglobin polymerization inhibitor, GBT601, which is a molecule discovered and designed by scientists at the Company. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||